It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new vessels in haematological malignancies and, in particular, in preleukaemic-myelodysplastic syndromes (MDS). In this study, bone marrow microvessel density (MVD) was assessed by immunohistochemistry and compared in trephine biopsies from 14 controls, five infectious disease (ID), 82 MDS, 15 acute myeloid leukaemia (AML) and 14 myeloproliferative disorder (MPD) patients. Statistical analysis (P < 0.001) demonstrated that MDS MVD was higher than in controls and ID (21 ± 9 vs 6 ± 2 and 10 ± 8 respectively) but lower than AML (30 ± 12) and MPD (40 ± 12). Among MDS-FAB subtypes, MVD was significantly higher in RAEB-t, CMML and fibrosis subsets compared to RA, RARS and RAEB subsets (P = 0.008). To further investigate angiogenesis machinery, the expression of vascular endothelial growth factor (VEGF) was evaluated by means of immunohistochemistry in control, MDS, AML and MPD biopsies. Even though VEGF mRNA expression was reported in the past in AML cell cultures and cell lines, in our samples VEGF expression was found to be particularly strong in most of the megakaryocytes but significantly less prominent in other cell populations including blasts. Since our findings suggest a correlation between angiogenesis and progression to leukaemia, additional work is now warranted to determine what regulates the generation of new vessels in MDS and leukaemia.
In vitro and in vivo laboratory studies and clinical data have generated ample evidence that neovascularization supports solid tumour viability and growth (Folkman, 1995) . Along this line, a recent paper from Perez-Atayde et al (1997) has suggested that angiogenesis might also play a pivotal role in human leukaemia. In fact, these authors have found a median of 42 vessels per 200ϫ field in bone marrow (BM) biopsies from paediatric acute lymphoblastic leukaemia (ALL) patients compared to a median of 6 vessels in normal controls. Differences between relapsed and non-relapsed patients were not significant, and chemotherapy did not decrease the number of vessels per field. Consistent with these data, increased levels of the endothelial cell mitogenic molecule basic fibroblast growth factor (bFGF) have been reported in the urine of paediatric ALL patients compared to controls. Again, chemotherapy did not significantly decrease bFGF concentration in the patients' urine. More indirect evidence of neovascularization in leukaemia comes from the observation that vascular endothelial growth factor (VEGF) is expressed by acute myeloid leukaemia (AML) cells and leukaemic cell lines and possibly act as a paracrine growth factor in the development of myeloid leukaemia (Fiedler et al, 1997) . Moreover, it has been proposed that angiogenesis and VEGF could play a cardinal role also in lymphoma (Foss et al, 1997; Salven et al, 1997) and myeloma (Vacca et al, 1994) development. We were interested in determining whether conversion of normal cells into preleukaemic-myelodysplastic (MDS), and ultimately leukaemic cells is a multistep process requiring the generation of new blood vessels. To this aim, we evaluated microvessel density (MVD) and VEGF expression in BM biopsies from healthy controls, infectious disease (ID), MDS, AML and myeloproliferative disorder (MPD) patients.
MATERIALS AND METHODS
We evaluated 133 paraffin-embedded BM biopsies collected from 1988 to 1998. BM biopsies were from 14 controls (solid cancer or Hodgkin's disease patients undergoing staging or follow-up and found to be free of neoplasia at histological examination), five ID, 85 MDS, 15 AML and 14 MPD patients. Among MDS patients, the median age was 67 years (range 26-86), 34% patients were female and 66% male. MDS, AML or MPD diagnosis was made according to FAB classification by means of BM aspirate stained with May-Grunewald-Giemsa and trephine biopsy stained with haematoxylin-eosin, Gomori and Giemsa. Ninety-four biopsies were fixed in B5, decalcified by EDTA (Mielodec, Bio-Optica, Milan, Italy) and embedded in paraffin in Milan, 39 were fixed in 10% buffered formalin, decalcified in 10% formic acid and embedded in paraffin in London. The immunohistochemical analysis was made by means of the avidin-biotin peroxidase complex (ABC) method using the 3,3′-diaminobenzidine tetrahydrochloride chromogen. The 4-µm-thick sections were immuno--stained with the following monoclonal antibodies: CD34-reactive QBEnd/10 (1:10 working concentration, Signet Laboratories Inc., Dedham, MA, USA), CD31-reactive 1A10 (1:50 working concentration, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), VEGF-reactive Ab-3 (1:100 working concentration, Oncogene Research Products, Cambridge, MA, USA). Slides were slightly counterstained with haematoxylin. For antigen retrieval, the slides were placed in a 0.1 M citrate buffer at pH 6.0 (VEGF and CD31), or in a 0.001 M EDTA buffer at pH 8.0 (CD34) and underwent three (VEGF and CD31) or four (CD34) 5-min 780W cycles at 90°i n a microwave oven. According to the manufacturer, biopsies from fetal kidneys and hormone-secreting prostate cancer patients were evaluated as VEGF-positive controls. The substitution of the primary antibody with non-immune mouse serum was used as negative control. MVD enumeration was made according to Perez-Atayde et al (1997) : in each sample a mean of 12 ± 7 microscopic fields (median 12, range 3-47) was evaluated at 250ϫ magnification, each field representing an area of 0.72 mm 2 . Any brown staining endothelial cell or endothelial cell cluster that was clearly separated from adjacent microvessels was considered a single, countable microvessel and vessel lumens were not a prerequisite to define a structure as a microvessel. Immunostaining of blasts and arterioles, clearly identifiable by the round shape and the presence of a central nucleus with one or more nucleoli, and by the presence of the media layer, were not counted. For each case, the median value of vessels and the field with the highest number of vessels ('hot spot') were recorded. Two readers evaluated slides in a blind fashion.
Statistical comparisons were performed using the linear regression analysis, the t-test, analysis of variance (ANOVA) and Student-Neumann-Keuls test in paired studies and the non-parametric analyses of Mann-Whitney, Wilcoxon and Kruskal-Wallis in non-paired studies. Values of P lower than 0.05 were considered as statistically significant. 
RESULTS
Best immunohistochemical results were obtained with anti-CD34 monoclonal antibody QBEnd/10, which depicted endothelial cells and a variable number of blasts. With this antibody, MVD intrareader variability was found to be 14 ± 10% (r = 0.879), thus indicating good reproducibility. By contrast, anti-CD31 invariably immunostained myeloid, lymphoid cells and megakaryocytes besides vessels, thus making difficult the microvessels count (Figure 1 A, B) . Therefore, only the results obtained with the QBEnd/10 antibody are given (Figure 1 B-J) . In three out of 85 MDS cases, CD34+ BM blast frequency was so high that MVD evaluation by means of CD34+ vessel enumeration was not feasible. Consequently, throughout the study we report data from 82 MDS cases. As shown in Table 1 , MVD and hot spots were similar in controls and ID, significantly higher in MDS than in controls and ID, significantly lower in MDS than in AML and MPD (P < 0.001 by ANOVA and Student-Neumann-Keuls test). Among FAB-related MDS subsets, MVD was significantly higher in the RAEB-t, CMML and fibrosis subsets compared to RA, RARS and RAEB subsets (P = 0.008). No significant differences were found between the RAEB-t, CMML and fibrosis MDSrelated subsets and AML patients. A detailed evaluation of the international prognostic scoring system (IPSS; Greenberg et al, 1997) was available in 29 out of 82 evaluated MDS patients, and in this subset MVD did not correlate significantly with age, gender, presence of chromosome abnormality and PLT count, whereas a weak trend indicated a higher MVD in patients with higher blast frequency, white blood cell (WBC) count and lower haemaglobin (Hb) levels (r = 0.20, 0.28 and 0.29 respectively). Detailed data about progression to AML were available for 22 patients. In this small group, MVD differences between patients who developed AML and patients who had stable MDS were not significant. In normal controls the vessels showed a straight shape ( Figure  1C ), whereas in MDS, AML and MPD there were basically three morphological types of vessels: large vessels with visible lumina and very irregular, branching shape (Figure 1 D, E) , sinusoids-like vessels ( Figure 1B) , and small vessels without discernible lumina (Figure 1 I, J) , which have been defined 'endothelial sprouts' by Perez-Atayde et al (1997) . Whereas these morphological variants were usually detectable in the same case, the first type predominated in MDS, the second in MPD and the third in AML. VEGF expression was usually found in the cytoplasm of megakaryocytes and histiocytes in normal controls, MDS and MPD, whereas the blast compartment was usually unreactive (Figure 1 K, L) . In particular, among AML patients we have observed few scattering VEGF expressing blasts representing less than 1% of the total blast population.
DISCUSSION
The seminal observation by Perez-Atayde et al (1997) of neovascularization in ALL BM environment prompted us to study MVD in preleukaemia-MDS BM biopsies. In fact, it has been suggested in the past that the growth of primary solid tumours is strictly dependent on their ability to induce angiogenesis from the surrounding vasculature, so that tumour progression, including invasion and metastasis, involves two different phases, prevascular and vascular (Gimbrone et al, 1972; Folkman, 1990) . Our finding that MDS has intermediate MVD levels between controls and AML might suggest a correlation between angiogenesis and progression to leukaemia, and it seems unlikely that increased MVD was solely due to hypercellularity. In fact, MVD observed in five cases with reactive hypercellular BM was comparable to that of normocellular control trephines. The correlation between angiogenesis and progression to leukaemia is further supported by the observation that MDS patients with enhanced blasts accumulation and, in particular, the RAEB-t in addition to CMML and fibrosis subsets, show an increased MVD. Regarding the CMML and fibrosis MDS subsets, our finding of an increased MVD compared to RA, RARS and RAEB subsets correlates well with recent observations of VEGF generation by solid tumour-associated macrophages (Lewis et al, 1995) and fibroblasts (Foss et al, 1997; Fukumura et al, 1998) . In fact, VEGF is currently considered the most relevant and the only endothelium-specific one among already known endothelial cell mitogenic factors, and it seems to be involved in the vascular phase of many different neoplastic diseases (Ferrara and Davis-Smyth, 1997) . Given that a recent report (Fiedler et al, 1997) has demonstrated VEGF mRNA generation from AML BM cells and leukaemic cell lines and VEGF protein generation in AML cell culture, one can speculate that leukaemic or even preleukaemic blasts might be among the principal providers of VEGF in the BM environment. On the other hand, we have evaluated BM biopsies from controls, ID, MDS AML and MPD and have found that VEGF expression is particularly high in megakaryocyes and, on some occasions, in macrophages, but markedly less relevant or otherwise below the detection limit of our procedure in MDS and AML blasts. This finding is in accordance with previous reports (Mohle et al, 1997; Banks et al, 1998) indicating relevant VEGF expression along the megakaryocytic differentiation pathway, and also suggests that MDS or leukaemic blasts might not produce clinically relevant amounts of VEGF. Interestingly, in one particular MDS case a remarkably high frequency of VEGF-positive megakaryocytes was associated with high median MVD (26.5) and hot spot (40). Thus, we are currently evaluating whether megakaryocytes play a crucial role in MDS-related angiogenesis.
In a very recent paper, Fukumura et al (1998) have reported about transgenic mice expressing the green fluorescent protein (GFP) under the control of the promoter for VEGF. In this elegant model, spontaneous tumours induced by oncogene expression show strong stromal, but not tumour, expression of GFP, and the predominant GFP-positive cells are fibroblasts. This finding implies that the VEGF promoter might be activated by the tumour microenvironment, and suggests a crucial role for stromal cell collaboration in tumour angiogenesis. In this context, the evaluation of the angiogenic potential of BM stromal cells from MDS, AML and MPD patients remains a future challenge. We are currently evaluating VEGF receptors expression and the generation of other endothelial cell mitogenic factors among different BM cells of MDS, AML and MPD patients to gain more insight into the steps from normal to leukaemic BM microenvironment.
Although the clinical and prognostic relevance of neovascularization in MDS, AML and MPD remains to be fully evaluated, different clinical observations have already indicated that MVD (Weidner et al, 1991; Graham et al, 1994; Vacca et al, 1994; Fernandez-Acernero et al, 1998) , bFGF (Nguyen et al, 1994) and/or VEGF (Salven et al, 1997; Linderholm et al, 1998 ) levels correlate well with tumour staging and outcome in a number of malignancies. In this context, neoangiogenesis in haematological neoplastic diseases is of particular interest, because resting endothelial cells are known to generate stem cell factor (Yamaguchi et al, 1996) and Flt3-ligand (Solanilla et al, 1998) and VEGF-stimulated endothelial cells produce granulocytemacrophage colony-stimulating factor (GM-CSF; Fiedler et al, 1997) . These cytokines, in turn, act as growth factors for haematopoietic progenitors and possibly for neoplastic blasts. In conclusion, our data support an important role of neo angiogenesis in MDS, AML and MPD. Recent data obtained in animal models have demonstrated that anti-angiogenic therapy is highly promising in different experimental neoplastic diseases (Folkman, 1995; Bohem et al, 1997) . However, anti-angiogenic therapy may not be able to induce tumour regression but could inhibit further growth by a mechanism of 'tumour stabilization' (Harris, 1997) . In this frame of reference, it would be interesting not only to evaluate in experimental leukaemia models the effect of anti-angiogenic drugs, alone or in combination with established chemotherapy regimens, but also whatever anti-angiogenic treatment could have a role in delaying or even preventing disease progression in MDS patients.
